In animal models and in Phase 1/2 clinical trials, novel non-steroidal MR antagonists have a more favourable therapeutic index than spironolactone or eplerenone—that is, they carry a lower risk of hyperkalemia at therapeutic doses in heart failure and proteinuric CKD [50, 51]. Here, NR3C2 is linked to Hyperkalemia.